Literature DB >> 16093978

Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.

Alice S Whittemore1, Piera M Cirillo, David Feldman, Barbara A Cohn.   

Abstract

PURPOSE: Prostate specific antigen (PSA) is a serine protease produced by normal and malignant prostate epithelial cells. Serum PSA increases with age, due largely to age related increases in the prevalence of benign prostatic disease. Little is known about PSA distribution in young adulthood, when benign and malignant prostatic diseases are rare, or about how PSA within the normal range in youth relates to subsequent prostate cancer risk.
MATERIALS AND METHODS: We evaluated serum PSA and subsequent prostate cancer occurrence in a cohort of young black and white American men with a median age at blood draw of 34 years, who in 1959 to 1966 participated as the fathers of newborns enrolled in the Child Health and Development Study, and who were followed for several decades for prostate cancer. We examined associations between PSA in young adulthood and subsequent prostate cancer risk using a nested case-control design based on 119 black and 206 white cases with 2 control men matched to each case on race and year of birth.
RESULTS: Prostate cancer risk increased with increasing PSA in black and white men. The OR comparing risk in the highest to lowest quartiles of PSA was 4.4 (95% CI 2.0 to 9.6) in black men and 3.5 (95% CI 2.0 to 6.1) in white men. ORs relating risk to PSA were higher when analysis was restricted to cases diagnosed before age 65 years.
CONCLUSIONS: These findings suggest that PSA levels in young adulthood indicate increased risk of prostate cancer and, thus, they may be useful for targeting men for screening and early diagnosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093978     DOI: 10.1097/01.ju.0000169262.18000.8a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations.

Authors:  Brian T Helfand; Carly A Conran; Jianfeng Xu; William J Catalona
Journal:  Curr Opin Urol       Date:  2017-09       Impact factor: 2.309

Review 2.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

3.  Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.

Authors:  S Scott Sutton; E David Crawford; Judd W Moul; James W Hardin; Eric Kruep
Journal:  World J Urol       Date:  2016-01-11       Impact factor: 4.226

4.  The Early Determinants of Adult Health Study.

Authors:  E Susser; S Buka; C A Schaefer; H Andrews; P M Cirillo; P Factor-Litvak; M Gillman; J M Goldstein; P Ivey Henry; L H Lumey; I W McKeague; K B Michels; M B Terry; B A Cohn
Journal:  J Dev Orig Health Dis       Date:  2011       Impact factor: 2.401

5.  Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up.

Authors:  Marvin E Langston; Ratna Pakpahan; Remington L Nevin; Angelo M De Marzo; Debra J Elliott; Charlotte A Gaydos; William B Isaacs; William G Nelson; Lori J Sokoll; Jonathan M Zenilman; Elizabeth A Platz; Siobhan Sutcliffe
Journal:  Prostate       Date:  2018-05-30       Impact factor: 4.104

6.  Proteomic Profiling of Serial Prediagnostic Serum Samples for Early Detection of Colon Cancer in the U.S. Military.

Authors:  Stephanie Shao; Benjamin A Neely; Tzu-Cheg Kao; Janet Eckhaus; Jolie Bourgeois; Jasmin Brooks; Elizabeth E Jones; Richard R Drake; Kangmin Zhu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-21       Impact factor: 4.254

Review 7.  Vitamin D metabolism and action in the prostate: implications for health and disease.

Authors:  Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

8.  Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values.

Authors:  William J Catalona; Stacy Loeb
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

9.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Authors:  Hans Lilja; Angel M Cronin; Anders Dahlin; Jonas Manjer; Peter M Nilsson; James A Eastham; Anders S Bjartell; Peter T Scardino; David Ulmert; Andrew J Vickers
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

10.  Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.

Authors:  J Athene Lane; Joanne Howson; Jenny L Donovan; John R Goepel; Daniel J Dedman; Liz Down; Emma L Turner; David E Neal; Freddie C Hamdy
Journal:  BMJ       Date:  2007-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.